Patents Examined by Jeffrey S. Parkin
  • Patent number: 7939083
    Abstract: This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding such a polypeptide, vectors, host cells, trimeric complexes and compositions thereof.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: May 10, 2011
    Assignee: Progenics Pharmaceuticals Inc.
    Inventors: Antu K. Dey, John P. Moore, William C. Olson, Sai Prasad N. Iyer, Yun (Kenneth) Kang, Michael Franti
  • Patent number: 7935797
    Abstract: This invention provides methods for inhibiting fusion of HIV-1 to CD4+ cells which comprise contacting CD4+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4+ cells is inhibited. This invention also provides methods for inhibiting HIV-1 infection of CD4+ cells which comprise contacting CD4+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4+ cells is inhibited, thereby inhibiting the HIV-1 infection. This invention provides non-chemokine agents capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4+ cells. This invention also provides pharmaceutical compositions comprising an amount of the non-chemokine agent capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4+ cells effective to prevent fusion of HIV-1 to CD4+ cells and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: May 3, 2011
    Assignee: Progenics Pharmaceuticals Inc.
    Inventors: Graham P. Allaway, Virginia M. Litwin, Paul J. Maddon, William C. Olson
  • Patent number: 7919101
    Abstract: Provided herein are pharmaceutical compositions for the prophylactic and therapeutic treatment of HIV comprising combinations of HIV fusion/entry inhibitors that exhibit synergistic effect, including T-20 (enfuvirtide), T-1249, T-1144, C34, and sifuvirtide. Also disclosed are methods of treating HIV infection by administering such compositions.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: April 5, 2011
    Assignee: New York Blood Center
    Inventors: Shibo Jiang, Chungen Pan
  • Patent number: 7919100
    Abstract: The present invention concerns a modified polypeptide containing at least an immunodominant region and the connecting loop between N- and C-helices of gp41 ectodomain of HIV-1, wherein the connecting loop includes at least a linker fragment having: —a size convenient for keeping the native conformation of the interaction between N- and C-helices, and —an hydrophily sufficient to provide a soluble and stable trimeric form to said modified polypeptide.
    Type: Grant
    Filed: July 29, 2004
    Date of Patent: April 5, 2011
    Assignee: Mymetics Corporation
    Inventors: Sylvain Fleury, Marc P Girard, Marie-Gaëlle Roger, Nicolas Mouz, Pierre-François Serres
  • Patent number: 7917303
    Abstract: Methods for identifying a motif or a combination of motifs having a Boolean state of predetermined mutations in a set of sequences including a) aligning a set of sequences of ordered motifs represented by a single-character code, b) comparing a reference sequence with the set of sequences aligned in step (a), c) identifying motifs not having mutated simultaneously and/or motifs having mutated simultaneously at least once on at least one sequence of the set and not having mutated on another sequence of the set.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: March 29, 2011
    Assignee: Centre National de la Recherche Scientifique—CNRS
    Inventors: Anne Vanet, Michaela Muller-Trutwin, Thomas Valère, Sophie Brouillet, Emmanuelle Ollivier, Laurent Marsan
  • Patent number: 7910716
    Abstract: Embodiments of the invention provide processes for the selection of HIV-1 subtype (clade) C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof for use in prophylactic and therapeutic vaccines to produce proteins and polypeptides for the purpose of eliciting protection against HIV infection or disease. A process for the selection of HIV subtype isolates comprises the steps of isolating viruses from recently infected subjects; generating a consensus sequence for at least part of at least one HIV gene by identifying the most common codon or amino acid among the isolated viruses; and selecting the isolated virus or viruses with a high sequence identity to the consensus sequence. HIV-1 subtype C isolates, designated Du422, Du 151 and Du 179 (assigned Accession Numbers 01032114, 00072724 and 00072725, respectively, by the European Collection of Cell Cultures) are also provided.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: March 22, 2011
    Assignees: Medical Research Council, University of Cape Town Observatory, University of North Carolina at Chapel Hill, Alphavax, Incorporated
    Inventors: Robert Edward Johnston, Salim Abdol Karim, Lynn Morris, Ronald Swanstrom, Carolyn Williamson
  • Patent number: 7901685
    Abstract: This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell, but not a T cell-tropic isolate of HIV-1 to a CD4+ cell; and agents determined to be capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4+ cell, but not a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell. This invention also provides: agents capable of specifically inhibiting the fusion of a macrophage tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1; and agents capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 with a CD4+ cell susceptible to infection by a T cell-tropic isolate of HIV-1. The agents include but are not limited to antibodies.
    Type: Grant
    Filed: October 25, 2005
    Date of Patent: March 8, 2011
    Assignee: Progenics Pharmaceuticals Inc.
    Inventors: Graham P. Allaway, Virginia M. Litwin, Paul J. Maddon
  • Patent number: 7897332
    Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: March 1, 2011
    Assignee: Abbott Laboratories
    Inventors: Sheng C. Lou, Jeffrey C. Hunt, John G. Konrath, Xiaoxing Qiu, James W. Scheffel, Joan D. Tyner
  • Patent number: 7892562
    Abstract: Administration protocols for a fusion protein, matrix protein and psoralen inactivated HIV based immunogenic composition that induces an immune response to HIV. The immunogenic compositions are based on HIV biologically active fusion peptide, matrix peptide, or psoralen inactivated HIV. The number of doses is 3X. The starting dose for an adult is 1x109-1x1010. The starting dose for an adolescent is ½(1x109-1x1010). The starting dose for a pediatric patient is ¼(1x109-1x1010). The second dose will consist of 1/10th of starting concentrations. The third dose will consist of 1/100th of starting concentrations. This will facilitate a Th-1 response. The days of administration are days 1; 30; and 180. Alternatively the days of administration are days 1; 20-40; and 160-200. The site of administration is one that targets lymphatic tissue. Adjuvant is administered before, simultaneous with or after each dose of the immunogenic compositions.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: February 22, 2011
    Inventor: Nelson M. Karp
  • Patent number: 7888003
    Abstract: This invention relates to compositions and methods for the detection of HIV-1 antibodies employing polypeptides obtained from the Gag-p6 protein, the method comprising the steps of: (a) contacting a biological sample with a peptide having an epitope that is recognized by the anti-HIV-1 antibody where the contacting is under conditions sufficient to permit anti-HIV-1 present in the sample to bind to the epitope and form a peptide-anti-HIV-1 antibody complex; (b) contacting the formed peptide-anti-HIV-1 antibody complex with an anti-HIV-1 antibody binding molecule under conditions sufficient to permit the anti-HIV-1 antibody binding molecule to bind to anti-HIV-1 antibody of the formed peptide-anti-HIV-1 antibody complex and form an extended complex; said extended complex being immobilized on a solid support; and (c) removing unbound antibody from said extended complex; and (d) determining the presence or concentration of the anti-HIV-1 antibody in the biological sample by determining the presence or concentrat
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: February 15, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Hana Golding, Surender Khurana
  • Patent number: 7858298
    Abstract: This invention provides methods for inhibiting fusion of HIV-1 to CD4+ cells which comprise contacting CD4+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4+ cells is inhibited. This invention also provides methods for inhibiting HIV-1 infection of CD4+ cells which comprise contacting CD4+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4+ cells is inhibited, thereby inhibiting the HIV-1 infection. This invention provides non-chemokine agents capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4+ cells. This invention also provides pharmaceutical compositions comprising an amount of the non-chemokine agent capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4+ cells effective to prevent fusion of HIV-1 to CD4+ cells and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 13, 1999
    Date of Patent: December 28, 2010
    Assignee: Progenics Pharmaceuticals Inc.
    Inventors: Graham P. Allaway, Virginia M. Litwin, Paul J. Maddon, William C. Olson
  • Patent number: 7811577
    Abstract: Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides.
    Type: Grant
    Filed: May 27, 2005
    Date of Patent: October 12, 2010
    Assignees: Merck Sharp & Dohme Corp., Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Elisabetta Bianchi, Antonello Pessi, Romas Geleziunas, David Bramhill
  • Patent number: 7811580
    Abstract: Env-CD4 complexes and hybrids are disclosed that expose cryptic epitopes that are important in virus neutralization. Methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
    Type: Grant
    Filed: May 7, 2003
    Date of Patent: October 12, 2010
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Susan Barnett, Indresh Srivastava
  • Patent number: 7811578
    Abstract: Described herein are chimeric peptides comprising a soluble trimeric coiled-coil and all or a portion of the N-peptide region of HIV gp41. These molecules are stable, trimeric coiled-coils that inhibit HIV entry into cells, such as human cells. Such peptides can be further assessed to demonstrate their ability to serve as potent anti-HIV therapeutic molecules and thus, as therapeutic molecules or drugs.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: October 12, 2010
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Debra M. Eckert, Tara R. Suntoke, Peter S. Kim
  • Patent number: 7811573
    Abstract: The present invention concerns a method for prophylactic and/or therapeutic vaccination and/or treatment and/or diagnosis of HIV/AIDS, other infectious diseases, inflammatory and angiogenic diseases and tumours which utilizes a biologically active HIV-1 Tat protein, fragments or derivates thereof, as a module with one or more of the following features: antigen, adjuvant and targeting-delivery system to specific antigen-presenting cells including dendritic cells, endothelial cells and macrophages. In particular, it is claimed that Tat can be used only in its biologically active form as an antigen combined with one or more other antigens, to prime or to boost protective immune responses against itself as well as other antigens and/or to selectively deliver these antigen(s) as well as active compounds to dendritic cells, endothelial cells and macrophages, due to its capability of targeting these A PC and of activating their maturation and functions and of increasing Th-1 type immune responses as an adjuvant.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: October 12, 2010
    Assignee: Istituto Superiore di Sanita'
    Inventor: Barbara Ensoli
  • Patent number: 7803524
    Abstract: Immunologically active peptides which are derived from a novel immunodeficiency virus which has the designation MVP5180/91 are described. A diagnostic composition containing such a peptide and methods of detecting an antibody against a retrovirus that causes immune deficiency using such diagnostic composition are also described. A kit containing the immunologically active peptides is also described. An immunogen and method of immunizing a mammal against HIV infection using the immunologically active peptides is described. DNA encoding the peptides and methods of detecting nucleic acids encoding HIV viruses are also described.
    Type: Grant
    Filed: March 21, 2005
    Date of Patent: September 28, 2010
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Stefan Brust, Stefan Knapp, Manfred Gerken, Lutz G. Guertler
  • Patent number: 7794725
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 14, 2010
    Assignee: Trimeris, Inc.
    Inventors: Shawn O'Lin Barney, Dennis Michael Lambert, Stephen Robert Petteway
  • Patent number: 7790171
    Abstract: The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: September 7, 2010
    Assignee: Centre National de la Recherche Scientifique (C.N.R.S.)
    Inventors: Christian Devaux, Véronique Hebmann, Gilles Divita, Frédéric Heitz, Catherine May Morris, Jean Mery, Roger S. Goody
  • Patent number: 7790849
    Abstract: An isolated polypeptide includes the amino acid sequence shown in SEQ. ID No. 13 and an isolated nucleic acid encoding the polypeptide, such as an isolated nucleic acid including the nucleic acid sequence shown in SEQ. ID No. 17. The isolated polypeptide includes two heparin binding polypeptides connected in tandem and the isolated nucleic acid encodes these. The polypeptide and nucleic acid sequences can improve retroviral vector mediated gene transfer efficiency into target cells.
    Type: Grant
    Filed: September 30, 2008
    Date of Patent: September 7, 2010
    Assignee: Takara Bio Inc.
    Inventors: Kiyozo Asada, Takashi Uemori, Takashi Ueno, Nobuto Koyama, Kimikazu Hashino, Ikunoshin Kato
  • Patent number: 7790177
    Abstract: The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one covalent binding site of myristate (SEQ ID NOS: 1-3) on the HIV matrix protein. The present invention contemplates three categories of embodiments: protein or protein fragments (SEQ ID NO: 1), messenger RNA, or DNA/RNA (SEQ ID NOS:2-3). DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: September 7, 2010
    Inventor: Nelson M. Karp